Dominik Escher

Sectors: Entrepreneurs, Policy.

Dr. Escher has significant experience as a successful biotechnology entrepreneur and a leader in therapeutic development in both the start-up and corporate pharmaceutical environments.

He was a founder and CEO of ESBATech, selling the ophthalmology side of the business to Alcon. Dr. Escher was VP of R&D Alcon and a member of the Group’s Global R&D Leadership Team and, on acquisition of Alcon by Novartis, a member of the Novartis Institutes of Biomedical Research (NIBR) Global Ophthalmology Leadership Team. He was a founder of Delenex Therapeutics and served on the board of the company until acquisition by Cell Medica. Dominik co-founded and is Chairman of CDR-Life, a biotechnology company focusing on next generation biologics. Dominik launched and is a Partner of Pureos Bioventures, a VC fund investing in next generation biologics companies. He is a board member of the Swiss Biotech Association, which he has led as President since 2013.
Country: Zurich, Switzerland